---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006598"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:16:14.402314+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MetaVia Phase 2a DA-1241 hits ALT reduction of 22.8 U/L, CAP score down 23 dB/m in MASH patients

## Summary
- DA-1241 100 mg lowered ALT by 22.8 U/L (p<0.05 vs placebo) after 16 weeks in patients with baseline ALT 40-200 U/L.
- Liver fat (CAP) reduced 23.0 dB/m with DA-1241 100 mg vs 1.4 dB/m placebo; FAST score dropped from 0.559 to 0.371.
- HbA1c decreased 0.54%p at week 16 (baseline 6.99%); in type 2 diabetes subgroup, HbA1c fell 1.08%p.
- Inflammation and fibrosis biomarkers (hs-CRP, CCL2, TIMP1) improved significantly (p<0.05 vs placebo).
- Well tolerated; no TEAEs leading to discontinuation except one placebo; company plans end-of-Phase 2 FDA meeting H1 2025.

## SEC filing metadata
- accession: 0001558370-25-006598
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837025006598/0001558370-25-006598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837025006598/mtva-20250507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006598
- JSON: https://secwatch.observer/filing/0001558370-25-006598.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.